Squarepoint
OLMA icon

Squarepoint’s Olema Pharmaceuticals OLMA Stock Holding History

Squarepoint’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
738,552
+409,872
+125% +$9.12M 0.01% 1013
2025
Q4 		$8.22M Buy
328,680
+314,589
+2,233% +$5.6M 0.01% 1173
2025
Q3 		$138K Sell
14,091
-29,515
-68% -$177K ﹤0.01% 4045
2025
Q2 		$186K Buy
43,606
+20,673
+90% +$92.2K ﹤0.01% 4001
2025
Q1 		$86.2K Sell
22,933
-25,896
-53% -$130K ﹤0.01% 4260
2024
Q4 		$285K Buy
48,829
+32,860
+206% +$328K ﹤0.01% 4191
2024
Q3 		$191K Sell
15,969
-41,101
-72% -$525K ﹤0.01% 3699
2024
Q2 		$617K Sell
57,070
-16,519
-22% -$179K ﹤0.01% 2918
2024
Q1 		$833K Buy
73,589
+27,832
+61% +$359K ﹤0.01% 2725
2023
Q4 		$642K Buy
+45,757
New +$615K ﹤0.01% 2826
2023
Q2 		– Sell
-23,943
Closed -$83.1K – 3873
2023
Q1 		$83.1K Buy
+23,943
New +$97.7K ﹤0.01% 3005
2022
Q3 		– Sell
-20,515
Closed -$83K – 3298
2022
Q2 		$83K Sell
20,515
-9,297
-31% -$29.5K ﹤0.01% 2649
2022
Q1 		$127K Buy
29,812
+14,625
+96% +$80.6K ﹤0.01% 2572
2021
Q4 		$142K Buy
+15,187
New +$315K ﹤0.01% 2830

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Squarepoint's OLMA Position: Q1 2026 in Review

Squarepoint increased its Olema Pharmaceuticals (OLMA) stake by 125% in Q1 2026, buying an estimated $9.12M and bringing the position to 738,552 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #1013.

Squarepoint first reported a position in OLMA in Q4 2021 and has held it in 14 quarters since. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Squarepoint held 738,552 shares of Olema Pharmaceuticals worth $11M as of Q1 2026.
  • Squarepoint bought 409,872 Olema Pharmaceuticals shares in Q1 2026, an estimated $9.12M.
  • Olema Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1013 holding.
  • Squarepoint first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.